A real-world study found no significant improvement in breast cancer detection or recall rates with an FDA-approved AI mammography tool in a single-reader setting.
Key Details
- 1Study reviewed 24,520 screening mammograms post-AI and 21,630 pre-AI, all using digital breast tomosynthesis (DBT).
- 2Recall rate was 12.3% before and 12.8% after AI implementation (p=0.13).
- 3Cancer detection rate per 1,000 women was 6.7 pre-AI and 7 post-AI (p=0.69), indicating no significant difference.
- 4AI categorized 61.3% as low risk, 34.9% as intermediate, and 3.8% as elevated risk, with cancer detection rates in those groups at 0.5, 8.4, and 98 per 1,000, respectively (p<0.001).
- 5AI missed 15 out of 171 diagnosed cancers, mostly among low- and intermediate-risk cases not flagged by AI.
- 6Authors suggest AI may aid in patient risk stratification, but primary screening metrics did not improve.
Why It Matters
While prior European studies in double-reading environments showed AI could improve detection or reduce workload, this large U.S. study indicates no significant breast cancer screening benefit in single-reader practice. The findings highlight the need for more nuanced evaluation of AI tools in real-world clinical workflows and may guide future U.S. AI adoption and regulatory considerations.
Source
AuntMinnie
Related News
•Radiology Business
New AI Flags Uncertainty in Breast Cancer Imaging Predictions
University of Pittsburgh researchers developed an AI model that quantifies uncertainty in breast cancer diagnostic predictions to enhance trustworthiness.
•Radiology Business
Webinar to Showcase Successful AI Automation in Radiology Workflows
A webinar will provide insights from imaging leaders on expanding and optimizing AI-driven automation in radiology clinical workflows.
•Radiology Business
Everlywell Launches Direct-to-Consumer Mammography AI for Breast Cancer Risk
Everlywell now offers the FDA-authorized Clairity Breast AI tool for patients to assess breast cancer risk from their mammograms.